Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Short-term Investments (2020 - 2025)

Historic Short-term Investments for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $1.4 million.

  • Apellis Pharmaceuticals' Short-term Investments rose 415.15% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 415.15%. This contributed to the annual value of $1.3 million for FY2024, which is 1867.15% up from last year.
  • According to the latest figures from Q3 2025, Apellis Pharmaceuticals' Short-term Investments is $1.4 million, which was up 415.15% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Short-term Investments ranged from a high of $458.2 million in Q1 2021 and a low of $1.1 million during Q2 2023
  • Over the past 5 years, Apellis Pharmaceuticals' median Short-term Investments value was $1.4 million (recorded in 2025), while the average stood at $90.2 million.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Short-term Investments soared by 10026.7% in 2021 and then plummeted by 9961.58% in 2023.
  • Over the past 5 years, Apellis Pharmaceuticals' Short-term Investments (Quarter) stood at $60.4 million in 2021, then tumbled by 97.89% to $1.3 million in 2022, then fell by 12.49% to $1.1 million in 2023, then increased by 18.67% to $1.3 million in 2024, then grew by 8.17% to $1.4 million in 2025.
  • Its Short-term Investments was $1.4 million in Q3 2025, compared to $1.4 million in Q2 2025 and $1.4 million in Q1 2025.